The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase 2 study of pembrolizumab plus pemetrexed for older patients with non-squamous non-small cell lung cancer with PD-L1 tumor proportion score of less than 50%: CJLSG1901.
 
Yoshihito Kogure
Honoraria - AstraZeneca; Boehringer Ingelheim; Chugai Pharma; GlaxoSmithKline; Lilly Japan; MSD; Ono Pharmaceutical; Taiho Pharmaceutical; Takeda
Research Funding - Abbvie (Inst); AstraZeneca (Inst); Chugai Pharma (Inst); Fujifilm (Inst); GlaxoSmithKline (Inst); Janssen (Inst); MSD (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst); Sanofi (Inst)
 
Hiroya Hashimoto
Honoraria - Chugai Foundation for Innovative Drug Discovery Science
 
Haruko Daga
Honoraria - AstraZeneca; Chugai/Roche
 
Yasushi Fukuda
Speakers' Bureau - AstraZeneca; Boehringer Ingelheim France; Bristol Myers Squibb Foundation; Chugai Pharma; Lilly; Merck; Novartis; Ono Pharmaceutical; Takeda
 
Akihiro Bessho
Honoraria - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb Japan; Chugai Pharma; Lilly Japan; Novartis; Ono Pharmaceutical; Pfizer; Taiho Pharmaceutical
Research Funding - Abbvie (Inst); AstraZeneca (Inst); Chugai Pharma (Inst); MSD K.K (Inst); Pfizer (Inst)
 
Tadaaki Yamada
Honoraria - Lilly
Research Funding - AstraZeneca (Inst); Janssen; Ono Pharmaceutical; Pfizer; Takeda
 
Yukihiro Toi
Speakers' Bureau - AstraZeneca; Bristol-Myers Squibb; Chugai Pharma; MSD; Ono Pharmaceutical; TAIHO PHARMACEUTICAL
 
Tomoki Kimura
Honoraria - AstraZeneca; Bristol-Myers Squibb Japan; Daiichi Sankyo/UCB Japan; GlaxoSmithKline; Lilly; Nippon Boehringer Ingelheim; Novartis; Sanofi
 
Hiroshige Yoshioka
Honoraria - Amgen; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Chugai Pharma; Daiichi Sankyo; Delta-Fly Pharma; Lilly; Merck; MSD K.K; Nippon Kayaku; Novartis; Ono Pharmaceutical; Otsuka; Pfizer; Taiho Pharmaceutical; Takeda
Consulting or Advisory Role - Delta-Fly Pharma
Research Funding - AstraZeneca (Inst); Boehringer Ingelheim (Inst); Daiichi Sankyo (Inst); Delta-Fly Pharma (Inst); Janssen (Inst); MSD (Inst); Novartis (Inst)
 
Koichi Azuma
Speakers' Bureau - AstraZeneca; Bristol-Myers Squibb; Chugai Pharma; MSD Oncology; Ono Pharmaceutical; Takeda
 
Naoki Furuya
No Relationships to Disclose
 
Yasutaka Fukui
No Relationships to Disclose
 
Hideo Saka
Honoraria - AstraZeneca; Chugai Pharma; Kaneka Corporation; Taiho Pharmaceutical
Research Funding - Janssen (Inst)
 
Masashi Kondo
Honoraria - AstraZeneca; Bristol-Myers Squibb; Chugai Pharma; Lilly; MSD K.K; Ono Pharmaceutical; Pfizer; pfizer; Takeda
Speakers' Bureau - AstraZeneca; Bristol-Myers Squibb; Chugai Pharma; DAIICHI SANKYO HEALTHCARE; Lilly; MSD; Ono Pharmaceutical; Takeda
Research Funding - AstraZeneca (Inst); Chugai Pharma (Inst); MSD (Inst); Ono Pharmaceutical (Inst); Takeda (Inst)